aplecheevlgupy.blogspot.com
Major depressive disorder affects nearly 15 millionm Americans and is the leading cause of disability inthe U.S. for peoplw between the ages of 15and 44, according to the National Institutes of Mental Health. The Winston-Salem-based Targacepy (NASDAQ: TRGT) said the trial showed that patientw who used the existing drug treatment citalopram augmented with its experimental known for nowas TC-5214, showed statistically significanty improvements in levels of depression, disability and other measuresa than patients who were givem citalopram plus a placebo.
One patient duringy the trial suffered a seizure which could have been related to either the citalopramk orthe TC-5214, but overall study investigators found TC-5214 to have "favorable tolerability," with the most frequent side-effectas being headache, dizziness and constipation. Targacept said it plan to present detailed results ofthe TC-5214 triap at the Society for Neuroscience meeting in October in Chicago. The company is activre in discussions with several pharmaceutical companies that could become a commercialization partnet forthe drug. Targacept will meet with the FDA and expectas to begin Phase 3 clinical developmentof TC-5214 in the second quarter of 2010.
The successfulo trial is the second piece of good news for Targacepythis month. On July 8, pharmaceutical giantt AstraZeneca announced it would keep pushingy ahead with Targacept on a drug that could become a treatmenyt forattention deficit/hyperactivity disorder or ADHD, and made a $10 millioh milestone payment to Targacept for that drug's progress.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment